Consequently, we employed the F11R/JAM-A antagonistic peptide 4D [31, 32] that blocked the breast cancer cell adhesion to the inflamed endothelium, which was particularly evident for MDA-MB-231 cells (Fig. 4a). Here, F11R is linked to breast carcinoma.